Articles On Botanix Pharmaceuticals (ASX:BOT)

Summary Health House International has signed a non-exclusive distribution agreement with Dragonfly Biosciences. The agreement with Dragonfly would strengthen Health House’s product portfolio within Australia. The distribution agreeme...

Source: photolona, Shutterstock Summary Australian Primary Hemp has signed another retail distribution agreement with Coles Group Limited. Cannabis player Little Green Pharma has entered into a non-exclusive distribution agreement wit...

Source: janews, Shutterstock Summary ASX-listed cannabis player Botanix Pharmaceuticals has obtained ethics approval for BTX 1702 Phase 1b trial. Oncology player PharmAust PharmAust provided an update on its Phase IIb trial evaluating...

Botanix Pharmaceuticals (ASX:BOT) has announced it has received ethics approval for the BTX 1702 Phase 1b clinical study for the treatment of papulopustular rosacea and an expansion of the study design.

Australian clinical-stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced the expansion of its management team with the appointment of three executives in the US.

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are flat today following the company’s release of its FY21 half-year results on Friday night. At the time of writing, the Botanix share price is trading at 11 cents, the same price at which it...

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are edging lower today despite the company reporting it has received a research and development (R&D) tax refund. At the time of writing, the Botanix share price has fallen 3.45% lower to 1...

Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has published positive data from a human clinical study examining the safety, tolerability and efficacy of its BTX 1801 antimicrobial product.

Botanix Pharmaceuticals (ASX:BOT) shares have soared after a small clinical trial backed the feasibility of putting synthetic cannabis up the ... Read More The post Botanix soars after pot-up-nose study success appeared first on Stockhead.

Summary Clinical stage synthetic cannabinoid player Botanix Pharmaceuticals has announced positive top-line data from its Phase 2a BTX 1801 study. The Company has also been evaluating the potential for using BTX 1801 for nasal decoloni...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has returned from its trading halt with a bang on Wednesday. In morning trade, the clinical stage synthetic cannabinoid company’s shares are up 31% to a record high of 19 cents. Why is...

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are lifting off today after the company released its quarterly report. At the time of writing, the Botanix share price is trading 6.06% higher at 17.5 cents. What is driving the Botanix share p...

Despite a brief respite, the pot stock revival looks to still be on the cards. Botanix Pharmaceuticals Ltd [ASX:BOT] was certainly making a strong case for it anyway, with the BOT share price surging 18.5% higher at time of writing... The p...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has been on fire on Wednesday. At one stage today, the clinical stage synthetic cannabinoid company’s shares were up over 22% to a record high of 16.5 cents. In afternoon trade the Bot...

The research article represents the culmination of research collaborations involving leading antimicrobial researchers across the world.

Botanix Pharmaceuticals shares are on the rise after research showed that a synthetic cannabidiol formulation can kill so-called "superbugs". ... Read More The post Botanix collab with UQ confirms antimicrobial potential of CBD appeared fir...

The pot stock resurgence isn’t slowing down yet! Cannabis companies are still going strong. With biotech-focused Botanix Pharmaceuticals Ltd [ASX:BOT] leading the charge this morning... The post Botanix Share Price Rises 4% as Clinical Stud...

The company is developing a pipeline of product candidates that leverage the antimicrobial properties of cannabinoids with a BTX 1801 Phase 2a study for the prevention of surgical site infections well advanced.

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is trading higher today on news the company has completed its phase 2a clinical study for BTX 1801. In mid-morning trade, the Botanix share price was up 8% to 13.5 cents. It has since...

Summary Botanix Pharmaceuticals has completed BTX 1801 antimicrobial Phase 2a clinical study. The Company anticipates top-line data of the study to be available early in the next year. BTX 1801 Phase 2a clinical study was intended to...

Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it has successfully completed a Pre-Investigational New Drug meeting with the US FDA's Office of Infectious Diseases for its lead antimicrobial program, BTX 1...

Summary Cannabinoid pharmaceutical player Botanix Pharmaceuticals has completed a pre-IND meeting with the FDA’s Office of Infectious Diseases for clinical development of BTX 1801. The US regulatory body stated that the proposed plan an...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is surging higher today after a positive announcement. In the minutes after market open, shares in the synthetic cannabinoid company jumped as high as 11.5 cents. The Botanix share pri...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is soaring higher today following the release of its September quarter update. At the time of writing, the synthetic cannabinoid company’s shares are up 15% to a year-high of 11.5 cent...

The ASX is littered with lots of companies that show potential to become the next market darling. While I mostly invest in the mid-to-large cap space, I do look for small cap ASX shares that could deliver strong returns. Every company has...

ASX cannabis stocks are continuing their victory lap following yesterday’s decision by the TGA to re-classify low-dose cannabidiol (CBD) products. The TGA has made an interim decision to down schedule CBD products, including oil and pills,...

Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it has conducted an 'end of phase two' meeting with the US FDA in relation to the development of BTX 1503 for the treatment of moderate and severe a...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price surged more than 20% higher in early trade after the company released an announcement regarding a milestone achievement. What did Botanix announce? Prior to the market’s open this morn...

Since the start of March, six clinical trials involving cannabis treatments around the world have been halted or cancelled altogether due to COVID19 pandemic but 179 are still recruiting, according to the US registry ClinicalTrials.com. Mor...

North American pot stocks are roaring back from lows in March but the same cannot be said for their antipodean counterparts, many of which continue to wallow. The New Cannabis Ventures Global Cannabis Stock Index soared 26 per cent last wee...

The cohort of 33 pot (and pot-adjacent) stocks tracked by Stockhead followed the broader market higher in April, as the ASX200 climbed 8.8 per cent to post its best monthly gain in 32 years. The big news in cannabis this week came in the fo...

Investors have cheered confirmation the US FDA granted Botanix Pharmaceuticals' (ASX:BOT) first antibacterial product (BTX 1801) approval for the prevention of post-surgical infections.

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

This is a significant milestone for Botanix as BTX 1801 is the first cannabinoid-based program to receive the designation globally and represents a strong endorsement of Botanix’s data.

In amidst the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) unveiled an operational boost in the form of support from the FDA to fast track its first antibacterial product, B...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

As fears surrounding the Coronavirus drive the markets down, one ASX-listed pot stock could triumph amid the COVID-19 crisis. The Coronavirus, now known as COVID-19, emerged from Wuhan in China last December and has since sent shockwaves th...

Synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) has unveiled the next phase of development for its cannabinoid antimicrobial platform and lead program BTX 1801. Earlier today, Botanix declared it had achieved “significant p...

Neuren Pharmaceuticals (ASX:NEU) has been granted Rare Pediatric Disease (RPD) designation for its Rett syndrome treatment, a serious and rare neurological disorder mainly affecting little girls. The US Food and Drug Administration (FDA) gr...

As market watchers would know, cannabis stocks globally have had a wild ride over the last three years. The volatility is a natural by-product of any frontier market – full of stops and starts as companies try to build out their business mo...

With the health and life science sector being the ASX’s top performer last year, Western Australia is keen to join the party. The state government has formed an Industry Reference Group to come up with a five-year growth plan for the indust...

Only one prescription for medical marijuana has been issued by a doctor in the Northern Territory, according to Minister for Health Natasha Fyles. In a submission to the Senate inquiry into barriers to patient access to marijuana, Fyles sai...

For an industry that’s projected to reach $US20 billion ($29 billion) by 2024 in the US, the cannabidiol (CBD) market there is very much the wild west. A study from researcher Leafreport comparing 3500 products for the sale in the US from 5...

Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it is attending and key investor conferences in the US in January - the JP Morgan Healthcare and Dermatology Summit conferences.

Last year was a bear market for cannabis stocks globally. During 2019, the excitement that had followed the legalisation of marijuana in many jurisdictions was replaced by cautio as investors realised early forecasts weren’t necessarily ma...

On Thursday the S&P/ASX 200 index started the year on a mildly positive note. The benchmark index rose 0.1% to 6,690.6 points. Will the local share market be able to build on this on Friday? Here are five things to watch: ASX 200 expec...

This year was a difficult one for ASX cannabis shares as well as cannabis stocks globally with share prices worldwide retreating from previous highs. In Australia the medical marijuana industry remains in its infancy. Nonetheless, the init...

Marijuana is the hottest herb on the planet right now, but while investing in medical cannabis stocks could make you a fortune, it could also risk the house. After a flurry of activity on the ASX in 2017 as the sector kicked off following l...